Questcor regains some ground after Acthar hit but coverage concerns linger

On 20 September, Questcor Pharmaceuticals' stock recovered some of the value lost the previous day when the per-share price was cut almost in half after reports that US health insurance company Aetna would cover only one of the 19 approved indications for HP Acthar gel (repository corticotropin injection) (scripintelligence.com, 20 September 2012).